SOUTH SAN FRANCISCO, April 8, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today presentations of new data for cenicriviroc (CVC) at "The International Liver Congress," a conference organized by the European Association for the Study of the Liver (EASL). The conference is being held April 22-26 in Vienna, Austria.
"The results of CVC studies that will be presented by some of our academic collaborators at this year's International Liver Congress continue to expand the body of evidence supporting CVC's potential to reduce liver inflammation and fibrogenesis, which are the liver-damaging processes in non-alcoholic steatohepatitis, or NASH," said Laurent Fischer, M.D., chairman and CEO of Tobira Therapeutics.
Frank Tacke, M.D., professor of medicine in the Department of Gastroenterology, Metabolic Diseases and Intensive Care Medicine at University Hospital Aachen, commented: "In the acetaminophen-induced acute liver injury mouse model to be presented at the congress, CVC showed a pronounced reduction of the infiltration of monocytes and macrophages in the liver. These cells constitute a major pro-inflammatory component in chronic liver diseases like NASH and are considered a key factor in promoting liver fibrosis."
CVC presentations at EASL's International Liver Congress will include:
- Abstract number RS-2026 (oral presentation, April 23, 4:15 PM)
CCR2+ infiltrating monocytes promote acetaminophen-induced actue liver injury – therapeutic implications of inhibiting CCR2 and CCL2
O. Krenkel; J. Mossanen; C. Ergen; F. Heymann; E. Lefebvre; D. Eulberg; C. Trautwein; F. Tacke
- Abstract number P0906 (poster session, April 24, 1:00 PM)
Inhibition of HCV replication by CCR5 blockade with cenicriviroc and maraviroc
K. Sherman; L. Kong; J. Blackard
- Abstract number P0146 (poster session, April 25, 10:00 AM)
Oral, once-daily, cenicriviroc leads to rapid and potent CCR2 and CCR5 blockade in subjects with advanced liver disease, similar to effects seen in healthy volunteers and HIV-1 infected subjects
N. Utay; M. Gottwald; W. Change; M. Willett; E. Lefebvre
About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV-1. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV-1. Tobira is actively enrolling patients in a Phase 2b clinical trial called CENTAUR to evaluate CVC in patients with NASH and liver fibrosis. For additional information on the CENTAUR study, please visit clinicaltrials.gov using the identifier NCT02217475 or www.centaurstudy.com. On January 14, 2015, Tobira and Regado Biosciences (NASDAQ: RGDO) entered into a merger agreement that is expected to close in the second quarter of 2015. Learn more about Tobira at www.tobiratherapeutics.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively "forward-looking statements" within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Tobira Therapeutics and upon what management believes to be reasonable assumptions based on information currently available to it, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Tobira's control. Such statements can usually be identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would" be taken, occur or be achieved.
Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those inherent in drug development, whether Tobira will be able to obtain financing when needed or on favorable terms, and other risks described in Tobira's filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Tobira cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Tobira does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.
SOURCE Tobira Therapeutics, Inc.